REMARKS

Upon entry of this preliminary amendment, claims 1-10 will

be pending in this application. Claims 1 and 3 are independent.

Applicant has amended the claims to conform to U.S. patent

practice. Applicants have added claims 7-10 to remove multiple

dependent claims. Applicants have inserted an Abstract of the

Disclosure. Applicants have not raised any issue of new matter.

Conclusion

The specification is in the proper format. The present

claims define patentable subject matter and are in condition for

allowance.

Should the Examiner believe that a conference would be

helpful in advancing the prosecution of this application, she is

invited to telephone Applicants' Attorney at the number below.

If necessary, the Commissioner is hereby authorized in this,

concurrent, and future replies, to charge payment or credit any

overpayment to Deposit Account No. 02-2334 for any additional

6

Attorney Docket: 0-2002.737 US

fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

Mark W. Milstead

Registration No. 45,825

Akzo Nobel Pharma Patent Dept.

P.O. Box 318

29160 Intervet Lane

Millsboro, DE 19966 Tel: (302) 934-4395

Fax: (302) 934-4305

Enclosure: Abstract of the Disclosure

Attorney Docket: O-2002.737 US Customer No.: 31846

Customer No.: 31846 Express Mail: EV 561841285 US